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Abstract
Click-evoked otoacoustic emissions (CEOAEs) are echo-like sounds, generated by the inner ear in response to click-stimuli. 
A sex difference in emission strength is observed in neonates and adults, with weaker CEOAE amplitudes in males. These 
differences are assumed to originate from testosterone influences during prenatal male sexual differentiation and to remain 
stable throughout life. However, recent studies suggested activational, postnatal effects of sex hormones on CEOAEs. Ado-
lescents diagnosed with gender dysphoria (GD) may receive gonadotropin-releasing hormone analogs (GnRHa) in order to 
suppress endogenous sex hormones and, therefore, pubertal maturation, followed by cross-sex hormone (CSH) treatment. 
Using a cross-sectional design, we examined whether hormonal interventions in adolescents diagnosed with GD (62 trans boys, 
assigned female at birth, self-identifying as male; 43 trans girls, assigned male at birth, self-identifying as female), affected 
their CEOAEs compared to age- and sex-matched controls (44 boys, 37 girls). Sex-typical differences in CEOAE amplitude 
were observed among cisgender controls and treatment-naïve trans boys but not in other groups with GD. Treatment-naïve trans 
girls tended to have more female-typical CEOAEs, suggesting hypomasculinized early sexual differentiation, in support of a 
prominent hypothesis on the etiology of GD. In line with the predicted suppressive effects of androgens, trans boys receiving 
CSH treatment, i.e., testosterone plus GnRHa, showed significantly weaker right-ear CEOAEs compared with control girls. 
A similar trend was seen in trans boys treated with GnRHa only. Unexpectedly, trans girls showed CEOAE masculinization 
with addition of estradiol. Our findings show that CEOAEs may not be used as an unequivocal measure of prenatal androgen 
exposure as they can be modulated postnatally by sex hormones, in the form of hormonal treatment.
Keywords Click-evoked otoacoustic emissions · Estradiol · Testosterone · Gender dysphoria · Gonadotropin-releasing 
hormone analogs · Sex differences
Introduction
Otoacoustic emissions (OAEs) are sound waves that are 
produced in the cochlea and propagate back through the 
middle ear into the external ear canal. OAEs that appear in 
the absence of any external stimulus are called spontane-
ous OAEs (SOAEs). When OAEs occur in response to brief 
transient click-stimuli, they are called click-evoked OAEs 
(CEOAEs) (Kemp, 2002; Rodenburg & Hanssens, 1998). 
Generally, females have stronger CEOAEs and more numer-
ous SOAEs compared with males (McFadden, Loehlin, & 
Pasanen, 1996), and this sex difference in emission strength 
and frequency has repeatedly been observed in neonates 
(Burns, Hoberg Arehart, & Campbell, 1992; Morlet et al., 
1995; Strickland, Burns, & Tubis, 1985). Therefore, it is 
assumed that the sex difference in OAE amplitude develops 
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during the prenatal sexual differentiation of the fetus. It is 
thought that this fetal sexual differentiation is a result of 
organizational effects of sex hormones on a developing brain, 
causing it to become more female- or male-typical (Bao & 
Swaab, 2011). According to the organizational-activational 
hypothesis, these previously organized brain structures 
are activated by differences in sex hormone levels later in 
life, especially from puberty onwards. Although OAEs are 
reported to be relatively constant throughout life (Burns, 
2009, 2017; McFadden et al., 1996), they might also be acti-
vated later in life. Several animal studies support the notion 
that the weaker CEOAEs present in males originate from 
relatively high prenatal exposure to androgens (for review, 
see McFadden, 2008; McFadden, Pasanen, Valero, Roberts, 
& Lee, 2009). In addition, OAE studies in twins showing 
that women who shared the uterus with a male co-twin had 
“masculinized” OAEs (McFadden, 1993; McFadden et al., 
1996), provide indirect evidence for the dampening, organi-
zational effects of androgens on the human auditory system.
Individual differences in OAEs have been shown to be 
relatively stable throughout life (Burns, 2009, 2017; McFad-
den et al., 1996). However, hearing loss and/or ototoxic drugs 
may reduce or eliminate them (Probst, Lonsbury-Martin, & 
Martin, 1991), and there is some evidence of temporary 
changes induced by the menstrual cycle and use of oral con-
traceptives. Specifically, several studies suggested that OAEs 
fluctuate with the menstrual cycle, peaking around ovulation 
when levels of estradiol are high (Al-Mana, Ceranic, Dja-
hanbakhch, & Luxon, 2010; Bell, 1992; Haggerty, Lusted, 
& Morton, 1993; Penner, 1995). However, in a recent study 
the evidence regarding OAE fluctuation during the menstrual 
cycle was not supported (McFadden, Pasanen, Maloney, 
Leshikar, & Pho, 2018). A temporary change in OAEs might 
be elicited by testosterone as well; a negative relationship 
between seasonal variations in testosterone and emission 
strengths was reported in male adult monkeys (McFadden, 
Pasanen, Raper, Lange, & Wallen, 2006). Thus, in addition 
to its prenatal effects on CEOAEs, testosterone also may 
exert dampening effects on emission amplitudes postnatally. 
Seasonal fluctuations in serum testosterone levels in adult 
men were found to correlate negatively with their CEOAE 
amplitudes as well (Snihur & Hampson, 2012b). In another 
study, Snihur and Hampson (2012a) suggested that estradiol 
also may be involved in regulating the production of OAEs, 
at least in the cochleae of females. They showed that women 
using oral contraceptives (that suppress endogenous fluctua-
tions in estradiol) had “defeminized” weaker OAEs compared 
with a group of women undergoing a normal menstrual cycle 
(cf. McFadden, 2000). No association between differences in 
OAEs and circulating testosterone levels could be observed 
in the two female participant groups. Therefore, the authors 
concluded that their results might reflect differences in estra-
diol exposure with relatively higher levels of estradiol in nor-
mally cycling women resulting in more female-typical OAEs 
(Snihur & Hampson, 2012a).
Gender dysphoria (GD; American Psychiatric Associa-
tion, 2013) is the significant distress or problems in function-
ing someone experiences due to an incongruence between 
the experienced/expressed gender and the assigned sex at 
birth. One hypothesis about the etiology of GD is that atypi-
cal levels of sex hormones during a critical period of sexual 
differentiation mediate a sex-atypical programming of certain 
localized regions of the brain and thereby the development of 
an atypical gender identity in transgender individuals (Bao 
& Swaab, 2011).
Due to the putative relationship between prenatal andro-
gen exposure and CEOAE strength, CEOAE measurements 
have been used as a marker of prenatal androgen exposure. In 
a previous study, we indirectly investigated the relationship 
between the (atypical) development of gender identity and 
prenatal androgen exposure as estimated by CEOAE meas-
urements (Burke, Menks, Cohen-Kettenis, Klink, & Bak-
ker, 2014). Participants were 57 children and adolescents 
diagnosed with GD (24 had a male sex assigned at birth, 
self-identifying as female [referred to as “trans girls”], and 
33 had a female sex assigned at birth, self-identifying as 
male [referred to as “trans boys”]). The terms “trans boys/
girls” were chosen based on international guidelines saying 
“When employing references to a person’s assigned sex at 
birth, authors should use terms such as birth-assigned sex, 
or (if appropriate) legal sex, instead of natal male or natal 
female” (Bouman et al., 2017).
All participants were treatment-naïve and were either pre-
pubertal or in early adolescence. The control participants were 
65 boys (male sex assigned at birth) and 62 girls (female sex 
assigned at birth), all of whom had a gender identity congru-
ent with their birth-assigned sex. In this prior study (Burke 
et al., 2014), it was indeed found that the group of 6–14-year-
old (treatment-naïve) trans girls tended to have stronger, more 
female-typical CEOAEs compared to the male control group, 
while CEOAEs of trans boys were similar to those of the 
female controls. Also, in that study we replicated the previ-
ously observed sex differences in CEOAE response amplitudes 
with significantly stronger emissions in control girls than in 
control boys, but there were no sex differences between boys 
and girls with GD (Burke et al., 2014). These results, in line 
with several neuroimaging studies, suggest a less pronounced 
sexual differentiation in transgender individuals (Burke, Man-
zouri, & Savic, 2017, and for reviews, see Guillamon, Junque, 
& Gómez-Gil, 2016; Kreukels & Guillamon, 2016).
At the Center of Expertise on Gender Dysphoria at the VU 
University Medical Center, eligible adolescents diagnosed 
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with GD may start using gonadotropin-releasing hormone 
analogs (GnRHa) in order to suppress pubertal maturation, 
and thus the irreversible development of the secondary sex 
characteristics of their sex assigned at birth (Kreukels & 
Cohen-Kettenis, 2011). From the age of 16 years on, as an 
important step in the gender-affirming treatment, adolescents 
with GD also may receive cross-sex hormones (CSH; testos-
terone for trans boys and estradiol for trans girls), in addition 
to their treatment with GnRHa, in order to develop secondary 
sex characteristics of their experienced gender (Delemarre-
van de Waal & Cohen-Kettenis, 2006).
In the current study, based on the assumption that sex 
hormones also may exert activational effects (i.e., changes 
that can be both suppressing and enhancing) on CEOAEs 
postnatally, we investigated, using a cross-sectional design, 
whether hormonal interventions such as pubertal suppres-
sion and CSH treatment in transgender individuals affected 
their CEOAEs. We hypothesized that administration of estra-
diol in addition to suppression of endogenous testosterone 
production by means of GnRHa in trans girls would result 
in stronger emissions compared to controls matched on age 
and birth-assigned sex, similar to female-typical CEOAE 
response amplitudes. Conversely, administration of testoster-
one in addition to suppressing endogenous estradiol by means 
of GnRHa in trans boys was assumed to result in suppressed 
CEOAEs in trans boys compared to controls matched on age 
and birth-assigned sex. Lastly, we hypothesized that, for both 
groups, similar changes would occur with administration of 
GnRHa alone, although to a lesser extent. In a broader sense, 
this could provide additional information on the extent to 
which (suppression/addition of) sex hormones influence 
other physical characteristics of transgender people, in this 
case the inner ear, besides the previously observed effects on 
the secondary sex characteristics and the brain.
Method
Participants
A total of 81 boys and girls served as control participants, who 
were recruited via several primary and secondary schools in 
the Netherlands, and by inviting friends and relatives of the 
transgender participants. Out of these 81 controls, 66 had 
valid CEOAE recordings in both ears, nine were excluded 
from the left-ear analyses due to invalid left-ear recordings, 
and six participants were excluded from the right-ear analy-
ses due to invalid right-ear recordings (see Statistical Analy-
sis for the criteria of valid recordings). Thus, valid CEOAE 
data from 44 control boys and 37 control girls (Table 1) were 
used. These participants were divided into three groups age-
matched to the corresponding GD groups: “early adolescent” 
age-matched to a group receiving no hormonal intervention 
(treatment-naïve), “mid-adolescent” age-matched to those 
receiving GnRHa, and “late-adolescent” age-matched to 
those receiving GnRHa plus CSH.
A total of 106 children and adolescents diagnosed with 
GD were recruited at the Center of Expertise on Gender Dys-
phoria at the VU University Medical Center in Amsterdam. 
One participant was excluded due to invalid measurements 
in both ears. Out of the remaining 105 transgender partici-
pants, 91 had valid CEOAE recordings in both ears, nine 
were excluded from the left-ear analyses due to invalid left-
ear recordings and five participants were excluded from the 
right-ear analyses due to invalid right-ear recordings. The 
43 trans girls and 62 trans boys (Table 1) with valid left or 
right CEOAE data were divided into three groups accord-
ing to their hormonal intervention: treatment-naïve, pubertal 
suppression by means of GnRHa administration or GnRHa 
plus CSH treatment. The latter is further referred to as the 
CSH group.
The treatment-naïve group consisted of 10 trans girls 
and 15 trans boys (Mage = 13.2, SD = 2.0, range 10.3–17.3; 
Table 1) who did not meet the criteria to start GnRHa treat-
ment yet. The early adolescent control group consisted of 13 
boys and 15 girls (Mage = 12.5, SD = 1.8, range 10.8–16.3).
The puberty-suppressed groups consisted of 14 trans girls 
and 26 trans boys (Table 1) who had been treated monthly 
with injections of 3.75 mg triptorelin (Decapeptyl-CR®, 
Ferring, Hoofddorp, the Netherlands) for, on average, 
20.1 months (range 2–48 months), resulting in complete sup-
pression of gonadal hormone production. These participants 
had not yet reached the age limit to start CSH treatment, 
but were expected to receive CSH in the future. The mid-
adolescent control group consisted of 18 boys and 10 girls.
The CSH treatment groups consisted of 19 trans girls who 
received 17ß-estradiol  (Progynova®, Bayer, Mijdrecht, the 
Netherlands or  Cetura®, ACE Pharmaceuticals, Zeewolde, 
The Netherlands) on a daily basis for on average 22.7 months 
(range 5–47 months) and 21 trans boys who received a testos-
terone–ester mixture  (Sustanon® 250 mg/ml, Merck Sharp 
& Dohmebv, Oss, the Netherlands) every 2–4 weeks, for 
on average 11.8 months (range 2–28 months). CSH doses 
depended on the patient’s weight (trans girls) or body sur-
face area (trans boys), and the starting dosage varied with 
the subject’s age. Until the age of 16.5 years, the starting 
dosage for estradiol was 5 µg/kg each day and for  Sustanon® 
25 mg/m2 body surface area every 2 weeks. When older than 
16.5 years, the dosage was 1 mg  Progynova®/Cetura® daily or 
75 mg  Sustanon® every 2 weeks, respectively. All study par-
ticipants who were treated with CSH also received a monthly 
triptorelin injection in order to suppress endogenous gonadal 
sex hormone production. They already had been receiving 
monthly triptorelin injections in order to suppress endog-
enous puberty before addition of CSH. The late-adolescent 
control group consisted of 13 boys and 12 girls.
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In the present study, which aimed to focus on the hormone 
intervention effects on CEOAEs, we again included the data 
of the treatment-naïve transgender and control participants 
from our previous study (Burke et al., 2014). However, here, 
we selected only those transgender participants who were 
already in puberty, with a minimal tanner stage of 2 (Marshall 
& Tanner, 1969, 1970), in order to match the three hormonal-
intervention groups with regard to their (previous) endog-
enous sex hormone exposure. Note that they all had some 
level of endogenous gonadal hormone exposure and were 
matched to controls on age and birth-assigned sex. For the 
current study, we included data only of those control partici-
pants who were above the age of 10, because all transgender 
participants were older than 10 years as well. Thus, in the 
current study pubertal (Tanner > 1) treatment-naïve transgen-
der and cisgender control participants (age > 10), who also 
participated in our previous study (Burke et al., 2014), were 
included in addition to GnRHa- and GnRHa- plus CSH-
treated participants with GD.
Materials and Procedure
CEOAE recordings were performed with EZ-screen soft-
ware and with an Otodynamics echo-port system ILO288, 
in combination with a laptop computer. The apparatus was 
calibrated each time it was put online for use. CEOAEs were 
recorded at five frequency bands (1000, 1414, 2000, 2828 and 
4000 Hz) and in the Quick Screen (nonlinear) mode with a time 
window of 2.5–12.5 ms. CEOAE responses were measured 
in terms of dB SPL (decibel sound-pressure level). Each ear 
was tested for a fixed number of 250 clicks; the average emis-
sion response of the five frequency bands was used for further 
analyses. The click-stimulus input was set to approximately 
80 (± 2.3) dB, which is in accordance with a clinical protocol 
for CEOAE recordings (Hall, 2000). A probe with an appro-
priately sized foam ear tip, thereby causing minimal discom-
fort for the participant, was placed in the external ear canal to 
seal the cavity completely. The probe fit was evaluated by the 
noise-level rejection meter: CEOAE data were regarded useful 
when environmental noise levels did not reach a threshold of 
6 mPa. Participants were seated in a comfortable chair and were 
allowed to relax for a few moments prior to data collection. 
They were asked to relax their body and facial muscles during 
the recordings in order to ensure a low-noise measurement. 
Besides external noise, test order of the left and right ear also 
might influence the CEOAE recordings (Thornton, Marotta, 
& Kennedy, 2003); therefore, the right ear was tested first in 
each participant.
Table 1  Mean CEOAE 
amplitudes 1–4 kHz (in dB 
SPL) as a function of sex, 
condition, and ear
All control and treatment-naïve participants (except for three treatment-naïve trans girls) participated in our 
previous study (Burke et al., 2014)
a Total sample: All participants included in left-ear and/or right-ear analyses
b CEOAE = click-evoked otoacoustic emission
c Trans girls = individuals assigned male at birth
d Trans boys = individuals assigned female at birth
e GnRHa = gonadotropin-releasing hormone analog, puberty suppression
f CSH = cross-sex hormone treatment, estradiol for trans girls, testosterone for trans boys
Total  samplea Left-ear  CEOAEb Right-ear CEOAE
Age: M (SD), range N dB SPL: M (SD) N dB SPL: M (SD) N
Trans  girlsc 15.9 (2.4), 11.0–20.0 43 10.7 (4.1) 37 12.1 (3.8) 40
 Treatment-naïve 12.6 (0.9), 11.0–14.0 10 6 10
 GnRHa 15.2 (1.0), 13.3–17.1 14 14 13
 GnRHa + CSH 18.1 (0.8), 16.8–20.0 19 17 17
Trans  boysd 15.6 (2.3), 10.3–20.3 62 12.3 (4.7) 59 12.5 (5.2) 60
 Treatment-naïve 13.7 (2.4), 10.3–17.3 15 14 13
 GnRHae 15.0 (1.6), 12.3–18.0 26 25 26
 GnRHa + CSHf 17.8 (1.1), 16.3–20.3 21 20 21
Control boys 14.5 (2.4), 10.8–18.3 44 12.4 (3.5) 37 12.2 (3.6) 40
 Early adolescent 12.8 (1.9), 10.8–16.2 13 10 12
 Mid-adolescent 13.9 (1.9), 10.8–15.8 18 15 16
 Late adolescent 17.1 (0.8), 15.8–18.3 13 12 12
Control girls 14.8 (2.9), 10.8–18.5 37 14.1 (3.7) 35 15.5 (3.8) 35
 Early adolescent 12.2 (1.7), 10.8–16.3 15 14 15
 Mid-adolescent 15.1 (1.8), 11.5–16.4 10 9 10
 Late adolescent 17.9 (0.4), 17.3–18.5 12 12 10
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Statistical Analysis
CEOAE recordings (the mean of the five frequency bands) 
with an amplitude of at least 0.99 dB SPL and a “whole-wave 
reproducibility” of more than 0.69 were used for analysis; 
whole-wave reproducibility was calculated as the correlation 
coefficient of interleaved nonlinear responses (Berninger, 
2007). All recorded measurements were transferred to a 
database and analyzed using the Statistical Package for the 
Social Sciences, version 20 (SPSS Inc., Chicago, IL, USA).
Left- and right-ear emissions have previously been 
reported to differ in strength, with right-ear emissions being 
stronger than left-ear emissions, and sex differences were 
sometimes only observed in right-ear emission (Aidan, Lest-
ang, Avan, & Bonfils, 1997; Driscoll, Kei, & McPherson, 
2000; Ismail & Thornton, 2003; McFadden et al., 1996; 
Saitoh et al., 2006). Therefore, separate ANOVAs were con-
ducted for each ear’s CEOAEs. An independent factorial 
analysis of variance (ANOVA) was used to analyze overall 
group differences in right CEOAE amplitudes, with right-ear 
CEOAE as dependent variable and condition (GD; control), 
sex assigned at birth (male; female) and age-group (1. treat-
ment-naïve, early adolescent; 2. GnRHa, mid-adolescent; 3. 
GnRHa plus CSH, late adolescent) as independent variables. 
An identical independent factorial ANOVA approach was 
used to analyze differences in left CEOAE amplitudes.
Effects were considered statistically significant at p ≤ .05, 
and Bonferroni correction was applied post hoc to control for 
multiple comparisons. Cohen’s d was reported as an estimate 
of effect size for a mean difference between groups, where d 
was calculated as the difference between two means divided 
by the square root of the (weighted) mean of the variances 
corresponding to those two means (Cohen, 1988).
Results
Demographic information for the subjects in all study groups 
is provided in Table 1. The Kolmogorov–Smirnov test and 
Levene’s test confirmed normality of the CEOAE data and 
that homogeneity of variance between groups could be 
assumed.
The transgender groups and their corresponding control 
groups did not differ in age, and the distribution of (trans) 
boys and (trans) girls was equal for all groups (Table 1). This 
was tested with planned contrasts using one-way ANOVA, 
which revealed that there was no significant difference 
between the mean age of the treatment-naïve group and the 
early adolescent control group, t(49.00) = 1.52, p = .134, 
the GnRHa group and the mid-adolescent control group, 
t(45.83) = 1.72, p = .093 and the CSH group and the late-
adolescent control group, t(59.44) = 1.87, p = .066. Based 
on Pearson’s chi-square, there was no significant association 
between age-group and having a specific sex, χ2(5) = 6.42, 
p = .267.
Gender Dysphoria versus Control Condition
Sex differences (across age-group) in right-ear CEOAE 
amplitudes were observed in the control condition, but not 
in the GD condition. In addition, whereas no differences 
between age-groups (i.e., treatment groups for GD) were 
found in controls, right-ear CEOAEs were significantly 
weaker in participants with GD when receiving CSH (plus 
GnRHa) compared to treatment-naïve participants (see 
Table 1 and Fig. 1b). This was tested with between-subject 
comparisons of a 2 (condition) × 2 (sex) × 3 (age-group) 
independent factorial ANOVA for right-ear CEOAEs, which 
revealed a significant main effect of sex, F(1, 163) = 9.00, 
p = .003, with overall stronger right-ear emissions in partici-
pants assigned female at birth than in participants assigned 
male at birth, as expected from the literature (McFadden 
et al., 1996). In addition, when pooling over age and con-
dition there was a significant interaction between sex and 
condition, F(1, 163) = 4.09, p = .045; for control participants, 
females had stronger right-ear CEOAEs than males (norma-
tive sex difference), but trans boys and trans girls showed 
no differences in CEOAEs. Furthermore, a significant inter-
action was revealed between age-group and condition, F(2, 
163) = 3.89, p = .022. Post hoc Bonferroni-corrected com-
parisons revealed that treatment-naïve transgender partici-
pants had significantly stronger right-ear CEOAEs compared 
to those receiving CSH (plus GnRHa) treatment, p = .016. 
There were no (age-group) differences between control par-
ticipants. Right-ear emissions in control participants tended 
to be overall stronger than in transgender participants, but 
no significant main effect for condition was revealed, F(1, 
163) = 3.42, p = .066. No significant interactions between 
sex and age-group, or sex, condition and age-group were 
observed.
Similarly, in left-ear CEOAEs there were differences 
between transgender participants and controls, and between 
males and females (see Table 1 and Fig. 1a). This was tested 
with a condition-by-sex-by-age-group independent facto-
rial ANOVA for left-ear CEOAEs, which revealed a sig-
nificant main effect of sex, F(1, 156) = 5.19, p = .024, with 
overall stronger left-ear emissions in participants assigned 
female at birth than in participants assigned male at birth, 
as expected (see Fig. 1a). There also was a significant main 
effect of condition, F(1, 156) = 5.27, p = .023, with over-
all stronger CEOAEs in the control condition than in the 
GD condition. A trend for a main effect of age-group was 
observed, F(2, 156) = 2.47, p = .088. Post hoc Bonferroni-
corrected comparisons indicated overall, thus irrespective of 
condition, stronger left-ear CEOAEs in the treatment-naïve 
GD and early adolescent control participants compared to 
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those receiving CSH treatment and late-adolescent controls, 
p = .014. Meaning the younger groups showed stronger 
CEOAEs than the older groups. No significant interactions 
between sex and condition, sex and age-group, condition and 
age-group or sex, condition and age-group were revealed.
Hormone Intervention Effects
CSH-treated trans boys showed masculinized right-ear CEO-
AEs compared to late-adolescent control girls, in line with 
the hypothesized masculinizing effect of testosterone. How-
ever, no further statistically significant differences between 
groups with GD and matched control groups in either right-
ear or left-ear CEOAEs were revealed (see Fig. 1). This was 
tested by a one-way ANOVA for right-ear CEOAEs in all 
participants assigned female at birth (trans boys, control 
girls), with age-group as an independent variable. There 
were significant differences between the three transgender 
groups and their age-matched control groups, F(5, 89) = 3.53, 
p = .006. Planned contrasts revealed no difference between 
treatment-naïve trans boys and early adolescent control girls, 
d = 0.15. Trans boys receiving GnRHa treatment tended to 
have weaker CEOAEs compared to mid-adolescent con-
trol girls, t(89) = − 1.75, p = .083, d = 0.61, and trans boys 
receiving GnRHa plus testosterone administrations (i.e., 
CSH group) had significantly weaker right-ear CEOAE 
amplitudes compared with the late-adolescent control girls, 
t(89) = − 3.00, p = .004, d = 1.16.
One-way ANOVA for right-ear CEOAEs in all partici-
pants assigned male at birth (trans girls, control boys), using 
age-group as an independent variable, did not reveal any 
significant differences between the three groups with GD 
and their age-matched control groups. However, in the right 
ear, treatment-naïve trans girls tended to have stronger, thus 
sex-atypical CEOAEs than the early adolescent control boys, 
d = 0.41, while trans girls receiving GnRHa had similar CEO-
AEs as the mid-adolescent control boys, thus sex-typical, 
d = 0.01. Notably, a moderate effect size indicated that trans 
girls receiving GnRHa plus estradiol administrations had 
weaker, thus even exaggerated male-typical CEOAE ampli-
tudes, when compared with late-adolescent control boys, 
d = 0.62.
Two one-way ANOVAs for left-ear CEOAEs among those 
participants with the same birth-assigned sex, investigating 
group differences between (1) trans boys and control girls, 
and (2) trans girls and control boys, yielded no significant 
group differences for either sex (see Fig. 1a). However, in 
the left ear, moderate-to-large effect sizes indicated that trans 
boys receiving GnRHa plus testosterone administrations 
had weaker CEOAEs than the late-adolescent control girls, 
d = 0.60, and that trans girls receiving GnRHa plus estradiol 
administrations, again had weaker, exaggerated male-typi-
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Fig. 1  CEOAE response amplitude in the left (a) and right (b) ears 
of assigned-at-birth male and female control and GD groups for the 
three age/treatment groups. Error bars represent the 95% confidence 
interval. CEOAE, click-evoked otoacoustic emission; TN, treatment-
naïve; GnRHa, gonadotropin-releasing hormone analog, puberty 
suppression; CSH, cross-sex hormone treatment; trans girls, female 
gender identity, male assigned at birth; trans boys, male gender iden-
tity, female assigned at birth; early/mid/late, early/mid/late-adolescent 
age. Pulled over sex and condition, the early/TN group had signifi-
cantly stronger left-ear CEOAEs than the late/CSH group (*), right-
ear CEOAEs were significantly weaker in participants with GD when 
receiving CSH (plus GnRHa) compared to treatment-naïve partici-
pants (*), and the CSH-receiving trans boys had significantly weaker 
right-ear CEOAEs than the late-adolescent control girls (**),*p ≤ .05; 
**p ≤ .01
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(see Fig. 1a). In addition, small effect sizes indicated weaker 
left-ear CEOAEs in treatment-naïve trans girls than in early 
adolescent control boys, d = 0.39, and, as expected, weaker 
CEOAEs in trans boys receiving GnRHa therapy compared 
to mid-adolescent control girls, d = 0.37.
Discussion
In the present study, we examined whether CEOAE response 
amplitudes in adolescents diagnosed with GD differed as 
a function of their hormone treatment when compared to 
(birth-assigned) sex- and age-matched controls, and thus 
whether CEOAEs were affected postnatally by circulating 
sex hormones. In accordance with past demonstrations of 
the suppressive effects of androgens on CEOAEs (McFad-
den, 2008; McFadden et al., 2009), trans boys (female sex 
assigned at birth) who received testosterone treatment 
showed significantly weaker right-ear CEOAEs compared 
with age-matched control girls. Thus, testosterone adminis-
tration seemed to dampen or “defeminize” CEOAE response 
amplitudes. Note that participants receiving testosterone (or 
estradiol) always received GnRHa as well, beginning before 
the start of CSH treatment. Therefore, this effect may be 
attributed to the addition of exogenous hormones as well 
as to the (long-term) suppression of endogenous hormones. 
As can be inferred from Fig. 1, pubertal suppression with 
GnRHa in trans boys tended to masculinize their CEOAEs, 
whereas a reverse effect of more feminized/demasculinized 
CEOAEs in the trans girls was not apparent. Moreover, con-
trary to our expectations that estradiol would exert enhanc-
ing effects on emission amplitudes, right-ear CEOAEs in 
trans girls receiving estradiol administrations (in addition to 
GnRHa) were not different from those of the age-matched 
control boys. Thus, testosterone as well as estradiol (plus 
GnRHa) treatment had masculinizing, activational effects 
on right-ear CEOAEs, as suggested previously by Snihur and 
Hampson (2012a, 2012b).
Left-ear CEOAEs were not different for three treatment 
groups with GD and their age- and sex-matched control 
groups. This is in line with previous findings that left- and 
right-ear emissions differ in strength, with right-ear emis-
sions being stronger than left-ear emissions and that sex dif-
ferences were sometimes only observed in right-ear emis-
sions (Aidan et al., 1997; Driscoll et al., 2000; Ismail & 
Thornton, 2003; McFadden et al., 1996; Saitoh et al., 2006). 
As in our previous study (Burke et al., 2014), we will there-
fore further focus on the right-ear CEOAE results.
We confirmed a significant main effect of sex, indicat-
ing overall stronger right-ear CEOAEs in (at-birth-assigned) 
females than in males. However, a significant interaction 
effect of sex and condition also indicated that this typical 
sex difference pattern was not similarly observed for control 
and GD participants alike. Hence, across treatment groups, 
no differences in CEOAEs between trans girls and trans boys 
were found. More specifically, whereas treatment-naïve trans 
boys had sex-typical right-ear CEOAEs (compared with 
control girls; d = 0.15), those of the treatment-naïve trans 
girls tended to be increased relative to age-matched control 
boys, thus atypical for their sex assigned at birth (d = 0.41). 
This finding was not unexpected, since the treatment-naïve 
groups of the current study (N = 10 trans girls; 11–14 years 
of age) were a sub-sample selected from a larger group of 
pre- and early adolescent participants (N = 24 trans girls; 
6–14 years of age) of our prior study (Burke et al., 2014). 
In that study also, the larger group of 24 trans girls showed 
relatively, though not significantly, feminized right-ear CEO-
AEs compared with an age-matched cis-male control group 
(d = 0.48). Although speculative, but partially in support of a 
prominent hypothesis on the etiology of GD (Bao & Swaab, 
2011; Swaab, Chung, Kruijver, Hofman, & Ishunina, 2002), 
our findings in the youngest, treatment-naïve groups suggest 
a hypomasculinized early sexual differentiation in trans girls 
and a typically female early sexual differentiation in trans 
boys. However, due to the small sample sizes in our study, 
effects could as well be due to larger variability and should 
therefore be confirmed in larger samples.
Effects of Testosterone on Click‑Evoked Otoacoustic 
Emissions
In trans boys, testosterone treatment in addition to GnRHa 
had suppressive effects on their CEOAE response amplitudes 
when compared to late-adolescent control girls. To the best 
of our knowledge, this is the first study that investigated the 
effects of postnatal androgen administration on CEOAEs in 
trans boys. Postnatal androgen effects on CEOAEs in males 
previously have been suggested by studies in rhesus monkeys 
(McFadden et al., 2006) and men (Snihur & Hampson, 2012b). 
Associated with seasonal androgen fluctuations, CEOAEs in 
rhesus monkeys appeared to be weaker in winter time, when 
circulating testosterone levels were high (McFadden et al., 
2006). Similarly, CEOAEs in men correlated negatively with 
monthly fluctuations in blood testosterone levels (Snihur & 
Hampson, 2012b). Of note, trans boys receiving testosterone 
administrations already had been receiving GnRHa, which 
means that differences might not be solely attributed to (the 
addition of) testosterone. Ideally, future studies should include 
an additional group of late-adolescent trans boys, receiving 
GnRHa only, to address this issue. Our findings thus provide 
evidence for the dampening influences of a combination of 
pubertal suppression and postnatal androgens on CEOAEs.
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Effects of Estradiol on Click‑Evoked Otoacoustic 
Emissions
We found that estradiol administrations in addition to GnRHa 
had no significant effects on right-ear CEOAEs in trans girls 
when compared to late-adolescent control boys. In contrast, 
several previous studies had suggested that relatively high 
levels of estradiol, such as during ovulation, correlated posi-
tively with OAE frequency and amplitude during the men-
strual cycle (Al-Mana et al., 2010; Haggerty et al., 1993; 
Penner, 1995). In addition, McFadden, Pasanen and Callaway 
(1998) found a higher frequency of SOAEs in a trans woman 
after treatment with estrogen as compared to before the treat-
ment. However, our findings did not support the hypothesis 
of enhancing effects of estradiol on CEOAEs. Moreover, the 
moderate effect size (d = 0.62) comparing trans girls receiv-
ing GnRHa plus estradiol and late-adolescent control boys 
indicated even weaker, rather than the expected higher ampli-
tudes in the trans girls. This result, however, may be in line 
with two previous studies by McFadden (2000) and Snihur 
and Hampson (2012a) who showed that women using oral 
contraceptives had significantly weaker OAEs compared 
with normally cycling women. Likewise, the trans girls in 
our study receiving daily estradiol administrations as part 
of their CSH treatment showed suppressed CEOAEs com-
pared to age-matched control boys. These “masculinizing” 
effects of oral contraceptives on the auditory system have 
previously been suggested by Elkind-Hirsch, Stoner, Stach 
and Jerger (1992) and McFadden (2000), who found that 
OAEs and several auditory brainstem response measures 
were “defeminized” in women using oral contraceptives in 
comparison with female non-users. Also, as has previously 
been suggested by Haggerty et al. (1993) and Penner (1995), 
female-typical fluctuations in OAE amplitude and frequency 
seem to be dependent on a cyclical, pulsatile pattern of estra-
diol secretion. Accordingly, our results could be explained by 
the notion that a continuous administration of estradiol (as in 
both oral contraceptive use and CSH administration) results 
in more male-typical, thus weaker OAEs.
However, in a recent study by van Hemmen, Cohen-
Kettenis, Steensma, Veltman and Bakker (2017) no differ-
ences in CEOAEs between women using oral contraceptives 
and normally cycling women were found. An alternative 
explanation for the male-typical CEOAEs in trans girls may 
be that, in an (at-birth-assigned) male organism/body part 
(e.g., the inner ear), estradiol and testosterone show very 
similar activational effects. In support of this, several animal 
studies (reviewed in Baum, 2003; Bakker et al., 2006; Jost, 
1983) have suggested that both testosterone and estradiol 
may masculinize or defeminize the nervous system and elicit 
male-typical sexual behavior in adult, previously castrated, 
rodents. There is little evidence for a role of fetal estradiol 
in male-typical psychosexual differentiation, because men 
who have either a point mutation in the estradiol receptor 
gene or lack the aromatase enzyme have a male gender iden-
tity (reviewed in Baum, 2006). Nevertheless, there is evi-
dence for activational effects of estradiol on the brain in adult 
men. Indeed, a large clinical study (Finkelstein et al., 2013) 
showed that treatment with an aromatase inhibitor led to a 
significant decline in sexual desire in adult men. Feminizing 
effects of estradiol have been suggested by a study that found 
that monozygotic female twins exhibited more SOAEs than 
dizygotic or non-twin females (McFadden & Loehlin, 1995). 
Although speculative, this might be indicative of a positive 
association between prenatal estradiol exposure and femin-
ized SOAEs. But again, it should be noted that in the current 
study differences may not merely be attributable to estra-
diol, because late-adolescent trans girls also were receiving 
GnRHa before and during estradiol treatment.
Taking these findings together, both testosterone and 
estradiol (in addition to GnRHa) seem to be actively impli-
cated in facilitating or inhibiting the cochlear amplification 
mechanism and may thus actively “feminize” or “masculin-
ize” OAEs. It should be noted that the influence of GnRHa 
only on CEOAEs in late-adolescent participants with GD is 
unknown. Therefore, the effects in the CSH groups might be 
attributable to addition of estradiol/testosterone, a long-term 
GnRHa treatment, or an interaction between the two. Also, 
of note, both the possible testosterone-mediated dampening 
effects on CEOAEs in our trans boys and the weaker emis-
sions in trans girls receiving GnRHa plus estradiol admin-
istration may be explained by an estradiol-driven effect. 
Dependent on the target tissue, testosterone either may have 
a direct effect by binding to the androgen receptor or may be 
locally converted to estradiol by the enzyme aromatase and 
consequently bind to ERs to exert its effect.
Furthermore, testosterone and estradiol may exert their 
effects on OAEs during different time windows. The outer 
hair cells in the rodent as well as the human cochlea have 
been shown to contain the receptor types ERα and ERβ (Hult-
crantz, Simonoska, & Stenberg, 2006; Motohashi et al., 2010; 
Stenberg et al., 2001; Stenberg, Wang, Sahlin, & Hulcrantz, 
1999). In rats, both receptor types were reported to be up- 
or down-regulated dependent on different postnatal devel-
opmental stages, whereas no ER expression was observed 
during fetal development (Simonoska, Stenberg, Masironi, 
Sahlin, & Hultcrantz, 2009), suggesting that any estrogen-
sensitive mechanisms associated with auditory functioning 
may occur during postnatal life.
Thus, the dampening effects of the testosterone (plus 
GnRHa) treatment on CEOAEs in our trans boys may reflect 
a physiological estradiol-mediated mechanism, whereas 
the weaker emissions following estradiol treatment in the 
trans girls may be explained by similar activational effects 
of estradiol and testosterone on the male ear. Furthermore, 
testosterone seems to suppress CEOAEs both endogenously 
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and exogenously, whereas estradiol seems to only enhance 
CEOAEs endogenously.
GnRH Action and Quiescence
Trans boys receiving GnRHa (which suppressed any endog-
enous gonadal hormone production) had somewhat weaker, 
though not statistically significant, CEOAE response ampli-
tudes compared with the age-matched control girls. This is 
in line with the assumed enhancing effects of endogenous 
estradiol on CEOAEs in (birth-assigned) females (e.g., dur-
ing the menstrual cycle) (Bell, 1992; Haggerty et al., 1993; 
Penner, 1995).
In contrast, GnRHa administration in trans girls, thus 
suppressing the effects of endogenous testosterone, did not 
elevate their CEOAEs. However, we previously showed, and 
confirmed in the current study, that treatment-naïve trans 
girls already exhibit slightly stronger, more female-typical 
emission amplitudes, compared with control boys (Burke 
et al., 2014). Therefore, potential CEOAE enhancing effects 
of testosterone suppression might be relatively smaller in 
trans girls, because emission amplitudes in treatment-naïve 
trans girls were increased a priori (see Fig. 1b).
During childhood, the hypothalamic-pituitary–gonadal 
(HPG) axis is virtually quiescent until it is reactivated at 
the onset of puberty (Grumbach, 2002; Nathan & Palmert, 
2005). In male fetal development, by the end of the first tri-
mester of pregnancy (Grumbach, 2002), the hypothalamus 
starts to produce GnRH, which stimulates the production of 
gonadotropins and gonadal sex steroids. During the first few 
weeks after birth, GnRH secretion again increases signifi-
cantly in males, resulting in a second, postnatal testosterone 
surge between 1 and 3 months of life, followed by a gradual 
decrease to prepubertal levels by 4–6 months (Finegan, Bar-
tleman, & Wong, 1989; Waldhauser, Weissenbacher, Frisch, 
& Pollak, 1981). In females, the ovaries are relatively qui-
escent prenatally, but female infants show a similar, though 
somewhat later postnatal activation of the HPG axis as boys. 
High levels of estradiol are secreted by the ovaries during 
6–12 months after birth, which start to decline by 12 months 
of age, but continue until the age of 24 months (Grumbach, 
2002; Quigley, 2002; Waldhauser et al., 1981). Interest-
ingly, relatively weaker CEOAEs in girls and less distinct 
sex differences in emission strengths have been observed in 
pediatric (2–6 years of age) populations (Kapoor & Panda, 
2006; Lamprecht-Dinnesen et al., 1998) during childhood 
quiescence of the HPG axis. Neonates and infants during 
the first year of age, in contrast, have been reported to show 
significant sex differences in OAEs, similar to adult popula-
tions (Collet, Gartner, Veuillet, Moulin, & Morgon, 1993; 
Kapoor & Panda, 2006; Lamprecht-Dinnesen et al., 1998; 
Strickland et al., 1985). Therefore, sex differences in OAE 
frequency and amplitude are most distinct during periods of 
GnRH secretion, and thus during gonadal hormone action. 
Vice versa, in the current study, we showed that suppressing 
gonadal hormones by means of GnRHa indeed resulted in 
weaker CEOAEs.
Our results should be viewed in light of some limitations 
that may be addressed by future studies. Because we con-
ducted cross-sectional comparisons, no inferences regarding 
developmental changes in CEOAEs associated with the hor-
monal interventions in individuals with GD could be made. 
Therefore, prospective studies following transgender adoles-
cents during the different phases of hormonal intervention 
(prior to any intervention, during pubertal suppression and 
CSH treatment) should provide more direct evidence for the 
hypothesized relationship between gonadal hormone action 
and CEOAE amplitudes. Furthermore, the groups with GD 
should be compared to control groups without GD, not only 
matched with regard to age but also with regard to pubertal 
status, and to an additional late-adolescent GD group receiv-
ing GnRHa only.
In conclusion, our findings show that CEOAEs may 
not be used as an unequivocal measure of prenatal andro-
gen exposure as they can be modulated postnatally by sex 
hormone exposure, in particular in puberty, but also during 
hormonal treatment. We propose that postnatal variations in 
CEOAE amplitude may be mediated by estradiol-regulated 
mechanisms.
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